XML 63 R49.htm IDEA: XBRL DOCUMENT v3.21.2
Net Income (Loss) Per Share - Schedule of Diluted Net Loss Per Share (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Numerator        
Net income (loss) attributed to Inovio Pharmaceuticals, Inc. (numerator for use in basic and diluted net income (loss) per share) $ (60,169,041) $ 19,171,336 $ (196,711,130) $ (142,072,777)
Net Income (Loss) Attributable to Parent, Diluted $ (60,169,041) $ 19,171,336 $ (196,711,130) $ (142,072,777)
Denominator        
Weighted average number of common shares outstanding (denominator for use in basic net income (loss per share) (in shares) 210,304,836 165,355,540 207,455,684 148,656,454
Effect of dilutive potential common shares (in shares) 0 9,020,862 0 0
Denominator for use in diluted net income (loss) per share (in shares) 210,304,836 174,376,402 207,455,684 148,656,454
Net income (loss) per share, diluted (in dollars per share) $ (0.29) $ 0.11 $ (0.95) $ (0.96)
Net income (loss) per share, basic (in dollars per share) $ (0.29) $ 0.12 $ (0.95) $ (0.96)